TouchONCOLOGY got the chance to catch up with Rocio Garcia-Carbonero on the unmet needs and the emerging therapeutics in the treatment of NETS.
The abstract ‘A phase II/III randomized double-blind study of octreotide acetate with axitinib versus octreotide acetate with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107). ’ (ABSTRACT NUMBER: 360) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
Questions
- What are the major unmet needs in the treatment of NETS? (0:05)
- What are the most promising novel and emerging therapies for NETs? (2:20)
Disclosures: RGC has provided scientific advice and/or received honoraria or funding for continuous medical education from AAA, Advanz Pharma, Bayer, HMP, Ipsen, Merck, Midatech Pharma, MSD, Novartis, PharmaMar, Pfizer, Pierre Fabre, Roche, Servier and Sanofi, and has received research support from Pfizer, BMS and MSD.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
